In addition to the rights set for in Section 13.2.2, solely in the case of a Change in Control of ​ that occurs after ​ having completed all Initial Development Activities but before ​ having completed any Clinical Studies as referred to in Sections 3.1.4 or 3.1.7, respectively, [[Organization A:Organization]] shall have the right, in its sole discretion, to either require the Change in Control party to # promptly transfer such ongoing Clinical Studies to [[Organization A:Organization]], or # promptly wind down and terminate such ongoing Clinical Studies in a manner that is permitted under Applicable Law.

In addition to the rights set for in Section 13.2.2, solely in the event of a Change in Control of ​ that occurs prior to ​ having completed all Initial Development Activities, [[Organization A:Organization]] shall have the right, in its sole discretion, to either # require the Change in Control party to complete the Initial Development Activities in accordance with the terms and conditions of this Agreement, or # assume and complete some or all of the unfinished Initial Development Activities; provided, that the Change in Control party shall be required to complete any Initial Development Activities that [[Organization A:Organization]] elects not to assume and complete. If [[Organization A:Organization]] elects to assume and complete any of the unfinished Initial Development Activities, then to the extent requested by [[Organization A:Organization]] # ​ or the Change in Control party shall assign to [[Organization A:Organization]] any or all Third Party agreements relating to such Initial Development Activities (including agreements with contract research organizations, clinical sites, investigators and manufacturing providers), and # [[Organization A:Organization]] shall use Commercially Reasonable Efforts to perform the unfinished Initial Development Activities that [[Organization A:Organization]] has elected to assume and complete under this Section 13.2.2. In the event [[Organization A:Organization]] elects to assume any unfinished Initial Development Activities that involve Clinical Studies, ​ or the Change in Control party shall either transfer Control of such Clinical Studies to [[Organization A:Organization]] or its designee and cooperate with [[Organization A:Organization]] to ensure a smooth and orderly transition thereof that will not involve any delay or disruption of such Clinical Studies. […​…].